Preserved sensitivity to beta2-adrenergic receptor agonists in patients with type 1 diabetes mellitus and hypoglycemia unawareness. by Galan, B.E. de et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/50122
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Preserved Sensitivity to 2-Adrenergic Receptor Agonists
in Patients with Type 1 Diabetes Mellitus and
Hypoglycemia Unawareness
Bastiaan E. De Galan, Pieter De Mol, Lianne Wennekes, Bas J. J. Schouwenberg, and Paul Smits
Departments of General Internal Medicine (B.E.D.G., B.J.J.S., P.S.) and Pharmacology-Toxicology (P.D.M., L.W., P.S.),
Radboud University Nijmegen Medical Centre, 6500 HB, Nijmegen, The Netherlands
Background andObjective:Use of 2-adrenergic receptor agonists
has been advocated for the treatment of hypoglycemia unawareness
in type 1 diabetes. In vitro, however, hypoglycemia unawareness has
been associated with reduced 2-adrenergic sensitivity. Therefore, in
vivo sensitivity to 2-adrenergic receptor agonist stimulation was
compared between type 1 diabetic patients with and without hypo-
glycemia unawareness and nondiabetic controls.
Methods: Ten type 1 diabetic patients with hypoglycemia unaware-
ness, 12 type 1 diabetic patients with intact hypoglycemic awareness,
and 11 healthy controls were enrolled. 2-Adrenergic sensitivity was
determined by measuring the forearm vasodilator response to in-
traarterial infusion of salbutamol. Salbutamol was infused in six
increasing doses ranging from 0.003 to 1.0 g1min1dl1. Forearm
blood flow (FBF) was bilaterally measured by venous occlusion pleth-
ysmography. Diabetic patients received low-dose insulin before FBF
measurements to ensure that experiments were carried out under
normoglycemic conditions.
Results: At baseline, FBF was 1.9  0.3 ml1min1dl1 in controls,
2.3 0.4 ml1min1dl1 in patients with intact awareness, and 1.4
0.1 ml1min1dl1 in patients with hypoglycemia unawareness (P 
0.048 vs. aware patients). In response to salbutamol, FBF increased
9.1-fold in controls, 8.0-fold in patients with intact awareness, and
10.7-fold in patientswith hypoglycemia unawareness (PNS). Heart
rate increased in all groups due to systemic spillover of salbutamol but
appeared blunted, considering a greater fall inmean arterial pressure
in patients with hypoglycemia unawareness.
Conclusions: Sensitivity to 2-adrenergic receptor agonist stimula-
tion is preserved in type 1 diabetic patients with hypoglycemia
unawareness. (J Clin Endocrinol Metab 91: 2878–2881, 2006)
PATIENTS WITH TYPE 1 diabetes mellitus (T1DM) are ata continuous risk of iatrogenic hypoglycemia as a result
of insulin treatment, especially in a setting of blunted glucose
counterregulatorydefensesandhypoglycemiaunawareness. In
turn, hypoglycemia unawareness occurs as a consequence of
repeated iatrogenic hypoglycemic events and is closely linked
to defects in hormonal counterregulation, in particular to the
bluntedadrenaline response (1). To stimulate adrenergic action,
treatment with 2-adrenergic agonists has been advocated to
prevent nocturnal hypoglycemia clinically (2) and support
swift recovery from hypoglycemia (3). However, the applica-
bility of such treatment for patients with hypoglycemia un-
awareness might be offset when sensitivity to adrenergic stim-
ulation is reduced. Various groups have reported reduced
-adrenergic sensitivity in hypoglycemia-unaware T1DM pa-
tients when compared with control and hypoglycemia-aware
diabetic subjects, based on reduced cardiac chronotropic re-
sponses to isoproterenol (4–7). Although reversal of reduced
-adrenergic sensitivity could be achieved when hypoglyce-
mias were meticulously avoided (7), a single nocturnal hypo-
glycemic event was sufficient to decrease -adrenergic sensi-
tivity in T1DM patients with intact hypoglycemic awareness,
whereas it increased in nondiabetic controls (8).
There is evidence from in vitro studies that the reduced -
adrenergic sensitivity associated with hypoglycemia unaware-
ness is mediated through the 2-adrenergic receptor. In hypo-
glycemia-unawareT1DMpatientswith a reduced chronotropic
response to iv isoproterenol, 2-adrenergic receptors on mono-
nuclear leukocytes were found to express reduced affinity for
isoproterenol (9). In another study, 1 wk of intensive insulin
treatment reduced 2-adrenoceptor density on lymphocytes in
T1DM, themagnitudeofwhichcorrelatedhighlywith thenum-
ber of hypoglycemic events and with loss of hypoglycemic
awareness (10). These data contrast with an in vivo study in-
vestigating the effect of local perfusion with terbutaline, a 2-
adrenergic agonist, throughamicrodialysis catheter (11). In that
study, terbutaline-induced lipolysis and stimulation of adipose
and skeletal muscle tissue blood flow were not found to differ
between intensively treated (presumably hypoglycemia un-
aware) T1DM patients and control subjects. However, blood
flowwas assessed indirectly, using amodel that can be applied
only under the assumption of steady-state conditions (12).
Other than by in vitro (9, 10) or indirect (11) assessment, the
sensitivity of the 2-adrenergic receptor has not been tested
quantitatively in T1DM with hypoglycemia unawareness by a
validated in vivo technique. The purpose of the present study
was to compare 2-adrenergic sensitivity in vivo in T1DM pa-
tients with hypoglycemia unawareness to that in T1DM pa-
tients with normal hypoglycemic awareness and nondiabetic
controls. To quantify 2-adrenergic sensitivity, we measured
the vasodilator action of salbutamol, a selective 2-adrenergic
receptor agonist, using the perfused forearm technique (13).
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Subjects and Methods
Subjects
Written informed consent was obtained from 22 T1DM patients re-
cruited from the outpatient clinic of our hospital and 11 healthy controls
recruited by advertisement. All diabetic subjects were free of classical long-
term diabetic complications, except background retinopathy. Autonomic
neuropathy was excluded by normal responses to cardiovascular reflex
tests (i.e. heart rate response to Valsalva maneuver, heart rate variability to
deepbreathing, andbloodpressure responses to standingupand sustained
handgrip) (14). Themagnitudeofhypoglycemicawarenesswasassessedon
the basis of the score on a Dutch modification of a standardized hypogly-
cemia questionnaire (15). Patients with a score less than 3 (of maximal 10)
were classified as being hypoglycemia aware (n  12), and patients with
higher scores were classified as hypoglycemia unaware (n 10). Three of
the latter had previously participated in a trial in which their inability to
detect hypoglycemiawas objectified by a hypoglycemic clamp test (16). All
participants had a normal blood pressure and used no medication other
than insulin or oral contraceptives, except for one nondiabetic and one
diabetic subject whowere on stable T4 supplementation therapy for longer
than1yr. Seven subjectswere current smokers, one in the control groupand
three in each of the diabetic groups. All participants were requested to
abstain from caffeine-containing substances and smoking for at least 48 h,
from alcohol for at least 24 h, and from food intake at least 10 h before
experiments took place. Diabetic subjects were asked to perform blood
glucose self-measurements at least four times per day for at least 5 d
preceding the experiment and to reduce the bedtime insulin dose by 20%
on the preceding day to avoid nocturnal hypoglycemia. All patients
checked capillary glucose at approximately 0200 h, and in case of nocturnal
hypoglycemia, the test was canceled or postponed. The Radboud Univer-
sity Nijmegen Medical Centre Medical Ethics Committee approved the
study.
Procedure
All experiments took place in the morning in a quiet, temperature-
controlled room (23–24 C), with the subjects supine. The brachial artery of
the nondominant armwas cannulated (Angiocath 20-gauge; BecktonDick-
inson, Sandy, UT) under local anesthesia (Xylocaine 2%) for infusion of
salbutamol (Ventolin; GlaxoSmithKline, Zeist, TheNetherlands) and blood
pressure monitoring (monitor 378341A; Hewlett Packard GmbH, Bo¨blin-
gen, Germany). Intraarterial infusion rates were calculated per deciliter
forearm volume,measured bywater displacement. In the diabetic subjects,
an antecubital vein of the contralateral arm was cannulated for adminis-
tration of insulin (Actrapid; Novo Nordisk, Bagsvaerd, Denmark) and
glucose 20% (if necessary). After cannulation(s), a 30-min equilibration
period was allowed to pass before baseline variables were obtained. A
low-dose iv insulin infusion of 7–10 mU/minm2 body surface area was
initiated to obtain normoglycemia in the diabetic subjects. Because of in-
sulin’s (modest) vasodilator effect (17), the insulin infusionwas terminated
as soonasplasmaglucose levels fell to less than7.0mmol/liter; glucose 20%
was given as necessary to prevent hypoglycemia.
The ensuing experimental procedure was similar for all participants.
At constant flow rates, 5-min infusions of saline and incremental doses
of salbutamol diluted in saline vehicle (0.003, 0.01, 0.03, 0.1, 0.3, 1.0
gmin1dl1) were subsequently administered intraarterially. Fore-
arm blood flow (FBF) was measured during the final 2 min of each
dosing step in both arms, using electrocardiogram-triggered mercury-
in-silastic (Dow Corning, Midland, MI) strain gauge venous occlusion
plethysmography, as described previously (13). The mean of six to eight
FBF measurements was used for data analysis. Hand circulation was
eliminated during FBFmeasurements bywrist cuffs inflated 100mmHg
above systolic blood pressure. The succeeding salbutamol doses were
interrupted once by a 15-min drug-free interval for deflation of the wrist
cuffs to allow recovery of hand circulation.
Analytical methods
Arterial plasma glucose levels were determined in duplicate by the
glucose oxidation method (Beckman Glucose Analyzer II; Beckman,
Fullerton, CA). Plasma insulin levels were determined by RIA (16).
Hemoglobin A1c (HbA1c) was measured using HPLC (Bio-Rad Labora-
tories, Veenendaal, The Netherlands) with reference values of 4.8–6.2%.
Calculations and statistical analyses
Vasodilator responses to salbutamol were expressed as absolute FBF
and as increase in FBF above baseline values (FBF). The effects of
salbutamol on FBF and hemodynamic variables were analyzed by re-
peated-measures ANOVA. Differences in means were tested by Stu-
dent’s t test. For data that had no normal distribution, the Wilcoxon
signed rank test andMann-WhitneyU test were used to compare paired
and unpaired data, respectively. The 2 test was used to compare the
male-female distribution of the study population. The SPSS personal
computer software package (version 12.0; SPSS, Chicago, IL) was used
for statistical analyses. P  0.05 was considered statistically significant.
Data are presented as means  sem unless otherwise specified.
Results
Characteristics of the participants are shown in Table 1. As
agroup, thediabeticpatientswere slightlyolder andhadhigher
heart rate and blood pressure at baseline than the control sub-
jects. There was a preponderance of males among the unaware
diabetic patients and a preponderance of females among the
aware diabetic patients, but this difference did not reach sta-
tistical significance. HbA1c and fasting plasma glucose values
were lower and disease duration was longer in T1DM patients
with hypoglycemia unawareness, comparedwith patientswith
intact awareness. Insulin levels were significantly higher in
diabetic patients than controls at all time points (Table 2) but
despite intermittent insulin infusion remained relatively stable
for the duration of the experiment. Plasma glucose levels, albeit
significantly higher than in controls, remained around the up-
per value for the normoglycemic range in the diabetic patients
during FBF measurements.
The vascular response to salbutamol
Baseline values for FBF in the infusion arm were 1.9 0.3
mlmin1dl1 in control subjects, 2.3  0.4 mlmin1dl1 in
hypoglycemia-aware T1DM patients (PNS), and 1.4 0.1
mlmin1dl1 in hypoglycemia-unaware patients (P 0.048
vs. aware patients). Corresponding values in the noninfused
armwere 1.9 0.2, 2.0 0.2, and 1.6 0.2mlmin1dl1 (P
NS). The lowering of plasma glucose levels in the diabetic
patients did not affect FBF in either arm (data not shown).
Maximal FBF responses to salbutamol in the infused arm
were 14.9  1.3 mlmin1dl1 in controls, 14.6  1.3
mlmin1dl1 in hypoglycemia-aware diabetic patients, and
13.8  1.5 mlmin1dl1 in hypoglycemia-unaware diabetic
patients (Fig. 1), corresponding to 9.1-, 8.0-, and 10.7-fold
increases, respectively (P 0.001 for all groups). There were
no statistically significant differences between the groups for
TABLE 1. Baseline characteristics
Controls T1DM aware T1DM unaware
No. (male/female) 11 (6/5) 12 (4/8) 10 (7/3)
Age (yr) 28.3  8.1 33.3  11.5 38.8  9.7a
BMI (kg/m2) 24.2  2.5 25.0  1.9 23.8  2.3
Heart rate (bpm) 58  5 69  9a 63  9
MAP (mm Hg) 79  11 90  9a 93  11a
HbA1c (%) ND 8.7  1.2 7.6  0.7
b
Duration of diabetes (yr) 11.6  5.2 19.7  6.2b
Insulin dose (U/kg) 0.72  0.24 0.68  0.17
Data are in number or means  SD. ND, Not determined.
a P  0.05 vs. controls.
b P  0.05 vs. T1DM aware.
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either the maximal FBF response or the course of FBF (P 
0.7 byANOVA). Comparable resultswere obtainedwhen the
data were expressed as absolute or relative changes in FBF
from baseline (FBF).
In both controls and hypoglycemia-aware T1DM patients,
FBF in the noninfused arm increased 1.5-fold in response to
the highest salbutamol dose to 3.0 0.6 mlmin1dl1 in the
first (P 0.007) and 2.6 0.3 mlmin1dl1 in the latter (P
0.043), indicating a systemic effect. In T1DM patients with
hypoglycemia unawareness, salbutamol did not affect FBF in
the noninfused arm. Heart rate increased by 13  2, 11  2,
and 9 2 beats per minute (bpm) in controls, hypoglycemia-
aware, and hypoglycemia-unaware T1DM patients, respec-
tively (P 0.001 for all groups), whereas mean arterial pres-
sure (MAP) decreased in unaware diabetic patients (5  3
mm Hg, P 0.001) and controls (3 2 mm Hg, P 0.005)
but not in patients with intact awareness. Despite within-
group effects, the course of FBF in the noninfused arm and
heart rate and MAP did not differ among the three groups
when tested by ANOVA.
Stratification according to glycemic control and duration
of disease
Stratification of the diabetic patients (n 22) according to
HbA1c value yielded a low-HbA1c group [mean HbA1c 7.1%
(range 6.0–7.9), n  8], a middle-HbA1c group [8.1% (8.0–
8.3%), n 7], and a high-HbA1c group [9.5% (8.7–11.4%), n
7]. In response to salbutamol, FBF increased from 1.7  0.5
to 13.5  1.4 mlmin1dl1 in the low-HbA1c group, from
1.6  0.3 to 14.0  2.0 mlmin1dl1 in the middle-HbA1c
group, and from 2.4  0.5 to 15.3  1.7 mlmin1dl1 in the
high-HbA1c group (PNS byANOVA).When recalculating
FBF responses according to disease duration, FBF increased
from 1.9  0.3 to 15.4  1.3 mlmin1dl1 in patients with
amean disease duration of 9.9 (range 3–15) yr and from 1.9
0.4 to 13.1  1.4 mlmin1dl1 in patients with a mean
disease duration of 20.6 (17–33) yr (P  NS by ANOVA).
Discussion
Reduced -adrenergic sensitivity has been reported in
T1DM patients with hypoglycemia unawareness (9, 10). The
present study was conducted to test the involvement of the
2-adrenergic receptor in vivo. Therefore, the vasodilator re-
sponse to local administration of salbutamol was compared
among T1DM patients with hypoglycemia unawareness,
T1DM patients with intact hypoglycemic awareness, and
nondiabetic controls. Our finding of similar vasodilator re-
sponses does not support a role for the 2-adrenergic recep-
tor in reduced -adrenergic sensitivity. When the data were
expressed as fold increase from baseline, salbutamol elicited
even higher responses in unaware diabetic patients than the
other two groups, although these differences did not reach
statistical significance.
Our data extend those obtained previously with microdi-
alysis (11) but are at variance with in vitro studies reporting
reduced 2-adrenoceptor-mediated action in hypoglycemia-
unaware T1DM patients on basis of reduced 2-adrenergic
receptor density or affinity for isoproterenol on white blood
cells (9, 10). However, alterations in 2-adrenoceptor density
or binding affinity on white blood cells do not necessarily
reflect those on other tissues, such as the vascular wall. In
addition, white blood cells may not be a stable population,
especially after stress hormone release. Lymphocytes, gran-
ulocytes, and monocytes of various subsets that differ ac-
cording to receptor density and binding affinity from cells
already in the circulation can bemobilized by catecholamines
and cortisol (18). In contrast, the perfused forearm technique
is a validated in vivomethod to quantify tissue sensitivity to
vasoactive substances (10). Moreover, our findings remained
unaltered when the diabetic patients were stratified accord-
ing to tightness of glycemic control as crude marker of (the
risk for) hypoglycemia unawareness.
It is unlikely that the higher insulin levels in the two
diabetic groups affected our data. First, a significant vaso-
dilator effect of insulin requires 4-fold higher plasma con-
centrations than those achieved here (17); second, insulin
does not exert its vasodilator effects by modulation of -
adrenergic receptors (19). Moreover, insulin levels were
identical in the two diabetic groups throughout the experi-
ments, and baseline FBF, although mutually different, was
not dissimilar from that in controls.
Our study had some limitations. First of all, the groups
were incompletely matched for sex, age, and disease dura-
tion. The effect of the latter two parameters on 2-adrenergic
FIG. 1. Local FBF in the experimental arm during intraarterial in-
fusion of salbutamol. FBF increased in the experimental arms in all
groups (P  0.001) but to similar extent (P  NS between groups).
TABLE 2. Plasma glucose and insulin levels
Controls T1DM aware T1DM unaware
Glucose level (mg/dl)
Baseline 92  8 243  72a 211  42a,b
Prior to test 92  8 108  16a 111  17a
End of test 92  8 125  21a 131  29a
Insulin level (U/ml)
Baseline 9  4 30  43a 30  20a
Prior to test 13  5 27  14a 29  17a
End of test 10  4 21  12a 21  14a
Data are means  SD. To convert plasma glucose values to milli-
moles per liter, divide by 18; to convert plasma insulin values to
picomoles per liter, multiply by 6.
a P  0.05 vs. controls.
b P  0.05 vs. T1DM aware.
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sensitivity is probably negligible: vasodilator responses to
-adrenergic stimulation are age independent (20), and strat-
ification of our data according to disease duration did not
reveal an effect of diabetes per se. However, 2-adrenergic
sensitivity may differ by sex, with women probably having
a more profound responsiveness to 2-adrenergic stimula-
tion than men (21). In the present study, women were over-
represented in the hypoglycemia-aware diabetic group and
underrepresented in the unaware diabetic group, although
this difference did not reach statistical significance. A post hoc
analysis of our data by gender did not reveal differences in
2-adrenergic sensitivity between men and women in either
the control or diabetic group or when all subjects were
pooled (data not shown), although it should be acknowl-
edged that our study was not designed for that purpose. Yet
even when gender would have had an effect, a more bal-
anced matching according to gender would have resulted in
greater, not smaller, salbutamol responsiveness in the T1DM
patients with hypoglycemia unawareness.
Previous in vivo studies on -adrenergic sensitivity in di-
abetes used the isoproterenol sensitivity test (4–8), in which
-adrenergic sensitivity is expressed as the dose of iv iso-
proterenol that produces an increment in heart rate of 25 bpm
over baseline values. This heart rate increment is the conse-
quence of direct stimulation of cardiac 1- (and 2-) adre-
noceptors and an indirect baroreflex response to 2-adreno-
ceptor-mediated peripheral vasodilatation (22). When
reconciling data from studies using the isoproterenol test
with that of the current study, it seems plausible that hypo-
glycemia-associated reduction in -adrenergic sensitivity is
mediated by the 1-adrenergic receptor. In our study, the
heart rate response to systemic spillover of salbutamol in
T1DM patients with hypoglycemia unawareness appeared
blunted in view of the greater fall in blood pressure, which
lends support to this suggestion. However, subtle impair-
ments in baroreflex sensitivity, only to be detected by spec-
tral analysis (23, 24) but not by conventional tests, have been
found to correlate with diabetes duration. Because disease
duration was longer in patients with hypoglycemia un-
awareness, compared with patients with intact awareness in
both the current study and studies using the isoproterenol
test (4–6), a contribution of reduced baroreflex sensitivity to
the lower heart rate response cannot be excluded.
In conclusion, sensitivity to 2-adrenergic agonist stimu-
lation is not reduced in T1DM patients with hypoglycemia
unawareness. This observation may be of potential value
when treatment with 2-adrenergic agonists is considered to
support glucose counterregulation. Whether reduced -
adrenergic sensitivity in hypoglycemia unawareness is me-
diated through the 1-adrenergic receptor or impairments in
the baroreflex response pathway requires further study.
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